Editas Medicine (EDIT) Stock Overview
A clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EDIT Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Editas Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.81 |
| 52 Week High | US$4.54 |
| 52 Week Low | US$0.91 |
| Beta | 2.19 |
| 1 Month Change | -12.56% |
| 3 Month Change | -32.96% |
| 1 Year Change | 53.39% |
| 3 Year Change | -82.13% |
| 5 Year Change | -96.79% |
| Change since IPO | -90.05% |
Recent News & Updates
Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Nov 13
Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop
Nov 05Recent updates
Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Nov 13Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop
Nov 05Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 02Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Oct 14Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Sep 09There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump
Jul 22Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely
Jun 17Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%
May 21Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough
Mar 30We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Mar 13Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Jan 17Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding
Nov 20Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week
Nov 06Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Sep 26Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Shareholder Returns
| EDIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.1% | 2.1% | 0.3% |
| 1Y | 53.4% | 29.8% | 13.9% |
Return vs Industry: EDIT exceeded the US Biotechs industry which returned 29.8% over the past year.
Return vs Market: EDIT exceeded the US Market which returned 13.9% over the past year.
Price Volatility
| EDIT volatility | |
|---|---|
| EDIT Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EDIT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EDIT's weekly volatility has decreased from 19% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 246 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.
Editas Medicine, Inc. Fundamentals Summary
| EDIT fundamental statistics | |
|---|---|
| Market cap | US$176.69m |
| Earnings (TTM) | -US$199.83m |
| Revenue (TTM) | US$46.38m |
Is EDIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDIT income statement (TTM) | |
|---|---|
| Revenue | US$46.38m |
| Cost of Revenue | US$111.16m |
| Gross Profit | -US$64.78m |
| Other Expenses | US$135.06m |
| Earnings | -US$199.83m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | -139.66% |
| Net Profit Margin | -430.84% |
| Debt/Equity Ratio | 0% |
How did EDIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 11:47 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Editas Medicine, Inc. is covered by 25 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Joel Beatty | Baird |
| Alec Stranahan | BofA Global Research |